Literature DB >> 17161229

Nontraditional atherosclerotic risk factors and extent of coronary atherosclerosis in patients with combined impaired fasting glucose and impaired glucose tolerance.

Andrzej Surdacki1, Ewa Stochmal, Magdalena Szurkowska, Stefanie M Bode-Böger, Jens Martens-Lobenhoffer, Anna Stochmal, Artur Klecha, Kalina Kawecka-Jaszcz, Jacek S Dubiel, Bohdan Huszno, Zbigniew Szybiński.   

Abstract

Partially inconsistent data exist on mutual relations between nontraditional atherosclerotic risk factors, including the magnitude of insulin resistance (IR), as well as on their relevance for atherogenesis in the metabolic syndrome. Subjects exhibiting combined impaired fasting glucose and impaired glucose tolerance (IFG/IGT) are exposed to an exceptionally high risk for atherogenesis and development of type 2 diabetes mellitus. Because of islet Beta-cell dysfunction, the usefulness of commonly used indices of IR is limited in IFG/IGT. Our aim was to assess the relationship between extent of angiographic coronary artery disease (CAD) and nontraditional atherosclerotic risk factors (including IR by a clamp-based golden standard method) in IFG/IGT. Fifty-three subjects (32 men, 21 women; mean age, 55 +/- 11 years) with stable angina, preserved left ventricular systolic function, and IFG/IGT were divided into 3 groups: group A (no coronary stenoses >50%, n = 22), group B (1-vessel CAD, n = 15), and group C (2/3-vessel CAD, n = 16). Insulin sensitivity was quantified by a hyperinsulinemic euglycemic clamp technique and expressed as M. M value, plasma homocysteine (Hcy) level, and asymmetric dimethyl-L-arginine (ADMA)/L-arginine ratio were independent determinants of CAD extent as shown by forward stepwise discriminant function analysis. Compared with group A (M = 32.7 +/- 9.3 micromol/kg fat-free mass [FFM] per minute; Hcy, 8.1 +/- 1.4 micromol/L), lower M and higher Hcy levels were found in group B (M = 16.9 +/- 8.2 micromol/kg FFM per minute, P < .001; Hcy, 11.2 +/- 2.9 micromol/L, P = .003) and C (M = 16.4 +/- 7.8 micromol/kg FFM per minute, P < .001; Hcy, 12.8 +/- 3.9 micromol/L, P < .001). The ADMA/L-arginine ratio was increased in group C (0.0078 +/- 0.0011) compared with group A (0.0063 +/- 0.0013, P = .03) and B (0.0058 +/- 0.0012, P = .01). Multivariate correlates (P < .05) of plasma Hcy concentrations were M (beta = -.34 +/- .12, P = .008), creatinine clearance (beta = -.23 +/- .10, P = .03) and fasting insulin (beta = .25 +/- .12, P = .04). This indicates an additive contribution of IR, plasma Hcy, and elevated ADMA/L-arginine ratio to the extent of angiographic CAD in combined IFG/IGT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17161229     DOI: 10.1016/j.metabol.2006.08.023

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  9 in total

1.  Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study.

Authors:  Anke-Hilse Maitland-van der Zee; Amy Lynch; Eric Boerwinkle; Donna K Arnett; Barry R Davis; Catherine Leiendecker-Foster; Charles E Ford; John H Eckfeldt
Journal:  Pharmacogenet Genomics       Date:  2008-08       Impact factor: 2.089

2.  ADMA (asymmetric dimethylarginine) and angiogenic potential in patients with type 2 diabetes and prediabetes.

Authors:  Radosław Wieczór; Anna M Wieczór; Arleta Kulwas; Danuta Rość
Journal:  Exp Biol Med (Maywood)       Date:  2020-09-22

3.  The Relationship between Weight and CVD Risk Factors in a Sample Population from Central Iran (Based on IHHP).

Authors:  Alireza Khosravi; Afshan Akhavan Tabib; Imandokht Golshadi; Zahra Dana Siadat; Ahmad Bahonar; Sonia Zarfeshani; Hassan Alikhasi; Shahrzad Rezaee; Fatemeh Noori; Mohammad Hashemi Jazi; Zahra Khosravi
Journal:  ARYA Atheroscler       Date:  2012

4.  No Association of Proton Pump Inhibitor Use with Fasting or Postload Glycaemia in Patients with Cardiovascular Disease: A Cross-Sectional Retrospective Study.

Authors:  Olga Kruszelnicka; Marcin Kuźma; Iwona Z Pena; Ian B Perera; Bernadeta Chyrchel; Ewa Wieczorek-Surdacka; Andrzej Surdacki
Journal:  Int J Med Sci       Date:  2017-09-02       Impact factor: 3.738

5.  Hyperhomocysteinemia as a Metabolic Risk Factor for Glucose Intolerance Among High-Risk Groups of Chinese Adults.

Authors:  Xiaomeng Feng; Yuan Xu
Journal:  Med Sci Monit       Date:  2017-06-07

6.  Multimodal strategy to rescue the brain in mild cognitive impairment: Ketogenic oral nutrition supplementation with B vitamins and aerobic exercise.

Authors:  Stephen C Cunnane; Russell H Swerdlow; Marco Inzitari; Gloria Olaso-Gonzalez; José Viña
Journal:  Eur J Clin Invest       Date:  2022-05-12       Impact factor: 5.722

7.  Asymmetric dimethylarginine predicts decline of glucose tolerance in men with stable coronary artery disease: a 4.5-year follow-up study.

Authors:  Andrzej Surdacki; Olga Kruszelnicka; Tomasz Rakowski; Aleksandra Jaźwińska-Kozuba; Jacek S Dubiel
Journal:  Cardiovasc Diabetol       Date:  2013       Impact factor: 9.951

Review 8.  Endothelial effects of antihypertensive treatment: focus on irbesartan.

Authors:  Roberto Negro
Journal:  Vasc Health Risk Manag       Date:  2008

9.  Differential associations of angiographic extent and severity of coronary artery disease with asymmetric dimethylarginine but not insulin resistance in non-diabetic men with stable angina: a cross-sectional study.

Authors:  Olga Kruszelnicka; Andrzej Surdacki; Alain Golay
Journal:  Cardiovasc Diabetol       Date:  2013-10-09       Impact factor: 9.951

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.